Loading...
Evaluation of [(89)Zr]Trastuzumab-PET/CT in Differentiating HER2-Positive from HER2-Negative Breast Cancer
PURPOSE: To evaluate whether tumor uptake of [(89)Zr]trastuzumab can distinguish HER2-positive from HER2-negative breast cancer. METHODS: Women with HER2-positive (n=34) and HER2-negative (n=16) breast cancer underwent PET/CT 5 ± 2 days following [(89)Zr]trastuzumab administration. HER2 status was d...
Na minha lista:
| Udgivet i: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5955803/ https://ncbi.nlm.nih.gov/pubmed/29442264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4696-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|